Amarin
Corporation plc AMRN, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of a Notice of Allowance for U.S. Patent
Application Serial Number 13/282,145, titled "Method of Treating
Hypertriglyceridemia." The application includes claims intended to protect the
Vascepa indication approved in July 2012 by the U.S. Food
and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.
A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in